Navigation Links
Common drugs initiate a molecular pas de quatre at the surface of the cell membrane
Date:7/26/2011

Brussels, 25 July 2011 - G protein-coupled receptors (GPCRs) are popular drug targets, accounting for about one-third of approved drugs and many hundreds of drugs currently in development. They act as molecular switches that transduce extracellular signals by activating heterotrimeric G proteins (G proteins) located at the inside of the cell. Changes in shape of these proteins determine essential processes, including whether an eye detects light, a virus invades a cell or a drug slows a racing heart. GPCRs sit in the membranes of cells throughout the body. They pick up signals from outside the body such as odors, flavors or light and signals from within the body, such as neurotransmitters or hormones. Once those signals are transmitted to the inside of the cell, they activate intracellular G proteins, triggering a variety of biochemical pathways. Despite their importance in biology and medicine, the way G protein-coupled receptors couple the detection of a signals from the outside world to the activation of the G-protein at the inside of the cell has remained largely unknown an important obstacle to understanding their function.

In an article in Nature, scientists from Stanford University, University of Wisconsin and VIB-Vrije Universiteit Brussel now reveal the complete three-dimensional atomic structure of an activated GPCR the beta-2 adrenergic receptor (beta-2AR) in a complex with its G protein. This is an important step towards the understanding of how the receptors actually work.

Beta-2 AR is activated by the hormones adrenaline and noradrenaline. Activation of the receptor lies at the basis of the body's fight-or-flight response by speeding up the heart, increasing blood pressure and opening airways. As a result, it is a key target for anti-asthma and blood pressure medications.

Adrenaline binds from the outside of the cell to the adrenergic receptor that is embedded in the cellular membrane, causing the heterotrimeric G protein (Gs) to fall apart in two pieces (G-alpha-S and G-beta-gamma). One piece (G-alpha-S) transmits the adrenaline signal to an effector enzyme; the other piece (G-beta-gamma) transmits the signal to an effector ion channel.

Although the receptor beta-2AR been discovered 20 years ago, the exact mechanism of its function remained unknown, impeding improvements of the drugs that act on this receptor. To explain the function of this receptor, it was important to catch the signaling complex in the act, a dance in two parts featuring four key players: the hormone (adrenaline or noradrenaline), the receptor and the G protein that is built from G-alpha-S and G beta-gamma.

Now, 20 year later, this is exactly what the researchers Stanford University, University of Wisconsin and VIB-Vrije Universiteit Brussel have accomplished. They produced two key freeze-frame pictures of this dance. In January 2011, they produced the first images of an active receptor, coupled to a drug-like molecule that acts like the hormone. In a follow-up article in Nature, they now present the poignant moment in the ballet the four-partner embrace that includes the hormone, the receptor, G-alpha-S and G-beta-gamma. These findings provide the very first three dimensional insights in transmembrane signaling trough GPCRs, a molecular process that is considered to be one of the most fascinating problems in biology. The discovery is important because the interactions between the GPCR and G-alpha-beta-gamma are pharmacologically relevant and unlock the secrets of functional selectivity, the ability of different drugs to coax distinct downstream effects from a single kind of receptor.

Obtaining a 3D image of the Hormone:GPCR:G-alpha-beta-gamma complex proved to be very complicated. The large and membrane embedded complex is unstable, difficult to prepare and the components are difficult to express and purify. Jan Steyaert and Els Pardon in Brussels produced a Xaperone, that binds simultaneously on G-alpha-S and G-beta-gamma and holds these proteins together in the complex. The structure of this stabilized complex was determined using X-ray crystallography techniques. The Advanced Photon Source beamline 23 ID-B at the Aragon Synchrotron, one of the most powerfull X-ray sources worldwide was used as a molecular camera.


'/>"/>

Contact: Joris Gansemans
info@vib.be
32-924-46611
VIB (the Flanders Institute for Biotechnology)
Source:Eurekalert

Related biology news :

1. Study provides insight on a common heart rhythm disorder
2. Researchers identify Achilles heel of common childhood tumor
3. First comprehensive genomic study of common cold reveals new treatment targets
4. GUMC researchers hone in on new strategy to treat common infection
5. Hairspray is linked to common genital birth defect, says study
6. Common food additive found to increase risk and speed spread of lung cancer
7. Mayo Clinic: Brain disorder suggests common mechanism may underlie many neurodegenerative diseases
8. Scientists uncover evolutionary keys to common birth disorders
9. Common soil mineral degrades the nearly indestructible prion
10. Genetic testing not cost-effective in guiding initial dosing of common blood thinner
11. New vaccine developed for preventing uncommon cold virus
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/31/2017)... , Jan. 31, 2017  Spero Therapeutics, ... therapies for the treatment of bacterial infections, today ... of antibacterial candidates from Pro Bono Bio Ltd ... prevalence of multi-drug resistant forms of Gram-negative bacteria.  ... Anti Infectives Ltd, a PBB group company. ...
(Date:1/26/2017)... , Jan. 26, 2017  Crossmatch, a leading ... a new solution aimed at combatting fraud, waste and ... was introduced at the Action on Disaster Relief conference ... meeting point for UN agencies and foreign assistance organizations ... Fraud, waste and abuse are a largely unacknowledged problem ...
(Date:1/25/2017)... Jan. 25, 2017 The Elements of Enterprise ... lifecycle is comprised of a comprehensive set of ... of maintaining digital identities and providing a secured ... There are significant number of programs opted by ... time by optimizing processes and changing policies. However, ...
Breaking Biology News(10 mins):
(Date:2/24/2017)... ... February 24, 2017 , ... Chef Jodi Abel has returned ... Making stops in several cities, she gained a number of delicious recipes and new ... a town in South Africa’s Western Cape province. It is internationally renowned for ...
(Date:2/24/2017)... , Feb. 24, 2017 Symic Bio, a ... a new category of therapeutics, announced today the completion ... in peripheral artery disease. The trial will evaluate the ... therapeutic, in the reduction of restenosis following angioplasty. ... development milestone for SB-030," said Nathan Bachtell , ...
(Date:2/24/2017)... (PRWEB) , ... February 24, 2017 , ... FireflySci, Inc ... Founded in late 2014, FireflySci had the goal of bringing their powerful cuvette ... continues to shape the path that FireflySci is going on as they add yet ...
(Date:2/24/2017)... Feb. 24, 2017  OncoSec Medical Incorporated ("OncoSec") (NASDAQ: ... host a Key Opinion Leader event to highlight new ... and poster presentation at the upcoming 2017 ASCO-SITC Immuno-Oncology ... event will be held in-person and via live webcast ... 9:00 AM PST at the Lotte New York Palace ...
Breaking Biology Technology: